Navigation Links
CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
Date:10/18/2007

ATLANTA, Oct. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it will conduct its annual Cardiac Surgery Fellows Allograft Symposium on October 19, 2007, at the Company's corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provide a practical laboratory in which to demonstrate and practice the techniques for proper implant site preparation and allograft implantation.

The keynote speaker will be David C. McGiffin, M.D., Associate Director, Division of Cardiothoracic Surgery and Chief, Section of Cardiopulmonary Transplantation at the University of Alabama, Birmingham, Ala. The program will be attended by 27 surgery fellows from major U.S. surgical training institutions, and will be directed by Paul E. Stelzer, M.D., Senior Faculty, Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, N.Y.

Three additional distinguished cardiovascular surgeons complete the faculty of this program: John W. Fehrenbacher, M.D., Department of Cardiothoracic Surgery, CORVASC, Indianapolis, Ind; Francis Robicsek, M.D., Ph.D., Chairman, Department of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, N.C.; and Craig R. Saunders, M.D., Chairman, Cardiothoracic Surgery, Saint Barnabas Health Care System, Newark, N.J.

"The Cardiac Surgery Fellows Allograft Symposium creates a unique atmosphere in which to engage in thought provoking discussions about complex surgical procedures with leading cardiovascular surgeons in the field," said Dr. Stelzer. "The additional opportunity to practice allograft implantation techniques in a wet lab environment offers an invaluable educational opportunity for these cardiac fellows."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

Media Contacts:

D. Ashley Lee

Executive Vice President, Chief Operating Officer and

Chief Financial Officer

CryoLife, Inc.

Phone: 770-419-3355

Katie Brazel

Fleishman-Hillard

Phone: 404-739-0150


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Study explains unexpected conductivity of nanoscale silicon
2. Engineers chart semiconductors on the scale of atoms
3. NameProtect releases annual list of top trademarkers
4. Doyle says new contracts saving state more than $16 million annually
5. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
6. Annual Bioethics Forum to explore genetic testing
7. Annual Conference Honors Tech Grant Winners
8. Criticare gets OK to market portable cardiac monitor
9. Software to aid brain surgery is goal of Milwaukee startup
10. UW-Madison has 7 Sloan research fellows, top in nation
11. Symposium will include venture capital "coaching"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):